| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Basic Study |
| Article Title |
Unconjugated bilirubin alleviates experimental ulcerative colitis by regulating intestinal barrier function and immune inflammation
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Jia-Dong Zheng, Yan He, Heng-Yuan Yu, Yuan-Li Liu, Yi-Xuan Ge, Xue-Ting Li, Xue Li, Yan Wang, Meng-Ru Guo, Yi-Lin Qu, Xiao-Fa Qin, Ming-Shan Jiang and Xiu-Hong Wang |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Foundation of China |
81703232 |
|
| Corresponding Author |
Xiu-Hong Wang, MSc, PhD, Academic Research, Professor, Department of Biochemistry and Molecular Biology, Heilongjiang Provincial Science and Technology Innovation Team in Higher Education Institutes for Infection and Immunity, Harbin Medical University, 157 Baojian Rd, Harbin 150086, Heilongjiang Province, China. wangxh700417@aliyun.com |
| Key Words |
Ulcerative colitis; Unconjugated bilirubin; Intestinal barrier; Intestinal homeostasis; Digestive proteases; Inflammation |
| Core Tip |
Intestinal function and microbiota are desired therapeutic endpoints for treatment of inflammatory bowel disease. However, a major problem is the lack of powerful and safe drugs. Unconjugated bilirubin (UCB) has anti-inflammatory and antitoxin effects. We found that UCB significantly decreased intestinal permeability and improved intestinal barrier function; regulated composition of gut microbiota; and relieved intestinal inflammation through suppressing the Toll-like receptor 4/nuclear factor-κB TLR4/NF-κB pathway. This study demonstrated that UCB ameliorates ulcerative colitis via intestinal barrier function through inactivating the digestive proteases and inhibiting immune inflammation through the TLR4/NF-κB signaling pathway. |
| Publish Date |
2019-04-18 05:48 |
| Citation |
Zheng JD, He Y, Yu HY, Liu YL, Ge YX, Li XT, Li X, Wang Y, Guo MR, Qu YL, Qin XF, Jiang MS, Wang XH. Unconjugated bilirubin alleviates experimental ulcerative colitis by regulating intestinal barrier function and immune inflammation. World J Gastroenterol 2019; 25(15): 1865-1878 |
| URL |
https://www.wjgnet.com/1007-9327/full/v25/i15/1865.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v25.i15.1865 |
